ERBB2 and gastric cancer: Our preplanned sensitivity analysis of NmiR-148a-3p in the PLATFORM sub-study identified a statistically significant difference in 3-month PFRs between normalised miR-148a-3p LOW versus HIGH in HER2-positive oesophago-gastric cancer patients treated with maintenance trastuzumab after the completion of trastuzumab-based chemotherapy.